Back

Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial

1 September 2024 (09:00 - 09:50)
Organised by: Logo
Congress Presentation Part of: Exercise in heart disease Obesity ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Elena Startseva

(Germany)

7 More presentations in this session

Presentation thumbnail
Improvement in cardiac function but not structure in adults born preterm following a prescribed moderate to high intensity exercise intervention: a randomized clinical trial
Associate Professor A. Lewandowski (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Effect of physical activity level on the association of LBBB, heart failure, and mortality
Doctor Y. Bitton (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Trajectories of physical activity among participants of six-month mobile app-based disease management program for cardiovascular risk: a group-based trajectory modelling approach
Assistant Professor T. Adachi (Nagoya, JP)
Abstract Slides Video
Presentation thumbnail
Regular supervised exercise training improves endothelial function, early atherosclerosis, arterial stiffness and endothelial progenitor cells in PCI patients.
Professor J. Park (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Changes in practice of exercise advice provision following the publication of ESC 2020 guidelines on sports cardiology and exercise at a central London inherited cardiac conditions outpatient service
Doctor N. Jayaratne (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Exercise in heart disease

The Event

Event poster

ESC Congress 2024

1 September 2024 09:00 CET
You may be interested in
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine
thumbnail
Congress Presentation
Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources